Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Procanbid: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Procanbid - General Information

A derivative of procaine with less CNS action. [PubChem]

 

Pharmacology of Procanbid

Procanbid is an agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Procanbid appears to be similar to that of procaine and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected.

 

Procanbid for patients

The patient should be encouraged to disclose any past history of drug sensitivity, especially to procaine or other local anesthetic agents, or aspirin, and to report any history of kidney disease, congestive heart failure, myasthenia gravis, liver disease or lupus erythematosus.

The patient should be counseled to report any symptoms of arthralgia, myalgia, fever, chills, skin rash, easy bruising, sore throat or sore mouth, infections, dark urine or icterus, wheezing, muscular weakness, chest or abdominal pain, palpitations, nausea, vomiting, anorexia, diarrhea, hallucinations, dizziness or depression.

 

Procanbid Interactions

If other antiarrhythmic drugs are being used additive effects on the heart may occur with procainamide administration, and dosage reduction may be necessary.

Anticholinergic drugs administered concurrently with procainamide may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for procainamide as for quinidine.

Patients taking procainamide who require neuromuscular blocking agents such as succinylcholine may require less than usual doses of the latter, due to procainamide effects on reducing acetylcholine release.

 

Procanbid Contraindications

Complete heart block

Procainamide should not be administered to patients with complete heart block because of its effects in suppressing nodal or ventricular pacemakers and the hazard of asystole. It may be difficult to recognize complete heart block in patients with ventricular tachycardia; but if significant slowing of ventricular rate occurs during procainamide treatment without evidence of A-V conduction appearing procainamide should be stopped. In cases of second degree A-V block or various types of hemiblock, procainamide should be avoided or discontinued because of the possibility of increased severity of block, unless the ventricular rate is controlled by an electrical pacemaker.

Idiosyncratic hypersensitivity

In patients sensitive to procaine or other ester-type local anesthetics, cross sensitivity, to procainamide is unlikely. However, it should be borne in mind, and procainamide should not be used if it produces acute allergic dermatitis, asthma or anaphylactic symptoms.

Lupus Erythematosus

An established diagnosis of systemic lupus erythematosus is a contraindication to procainamide therapy, since aggravation of symptoms is highly likely.

Torsades de Pointes

In the unusual ventricular arrhythmia called "les torsades de pointes" (twistings of the points) characterized by alternation of one or more ventricular premature beats in the directions of the QRS complexes on ECG in persons with prolonged Q-T and often enhanced U waves, Group 1A antiarrhythmic drugs are contraindicated. Administration of procainamide in such cases may aggravate this special type of ventricular extrasystole or tachycardia instead of suppressing it.

 

Additional information about Procanbid

Procanbid Indication: For the treatment of life-threatening ventricular arrhythmias. Mechanism Of Action: Procanbid is sodium channel blocker. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Drug Interactions: Amiodarone Amiodarone increases serum levels and toxicity of procainamideCimetidine The histamine H2-receptor antagonist increases the effect of procainamideRanitidine The histamine H2-receptor antagonist increases the effect of procainamideCiprofloxacin The quinolone increases the effect of procainamideLevofloxacin The quinolone increases the effect of procainamideOfloxacin The quinolone increases the effect of procainamideDihydroquinidine barbiturate Quinidine increases the effect of procainamideQuinidine Quinidine increases the effect of procainamideQuinidine barbiturate Quinidine increases the effect of procainamideRanolazine Possible additive effect on QT prolongationRivastigmine Possible antagonism of actionDonepezil Possible antagonism of actionGalantamine Possible antagonism of actionCisapride Increased risk of cardiotoxicity and arrhythmiasMesoridazine Increased risk of cardiotoxicity and arrhythmiasThioridazine Increased risk of cardiotoxicity and arrhythmiasTerfenadine Increased risk of cardiotoxicity and arrhythmiasZiprasidone Increased risk of cardiotoxicity and arrhythmiasVardenafil Increased risk of cardiotoxicity and arrhythmiasTrimethoprim Trimethoprim increases serum levels of procainamide Food Interactions: Not Available Generic Name: Procainamide Synonyms: Not Available Drug Category: Antiarrhythmic Agents Drug Type: Small Molecule; Approved Other Brand Names containing Procainamide: Biocoryl; Novocainamid; Novocainamide; Novocaine Amide; Novocamid; Procainamide Hcl; Procaine Amide; Procamide; Procan; Procan Sr; Procanbid; Procapan; Promine; Pronestyl; Pronestyl-Sr; Absorption: 75 to 95% Toxicity (Overdose): LD50=95 mg/kg (rat, IV); LD50=312 mg/kg (mouse, oral); LD50=103 mg/kg (mouse, IV); LD50=250 mg/kg (rabbit, IV) Protein Binding: 15 to 20% Biotransformation: Hepatic Half Life: ~2.5-4.5 hours Dosage Forms of Procanbid: Tablet, extended release OralCapsule OralSolution Intramuscular Chemical IUPAC Name: 4-amino-N-(2-diethylaminoethyl)benzamide Chemical Formula: C13H21N3O Procainamide on Wikipedia: https://en.wikipedia.org/wiki/Procainamide Organisms Affected: Humans and other mammals